Interleukin-23 secretion by donor antigen-presenting cells is critical for organ-specific pathology in graft-versus-host disease
Open Access
- 5 March 2009
- journal article
- Published by American Society of Hematology in Blood
- Vol. 113 (10) , 2352-2362
- https://doi.org/10.1182/blood-2008-08-175448
Abstract
Damage to the gastrointestinal tract during graft-versus-host disease (GVHD) from the conditioning regimen in conjunction with alloreactive donor T cells plays a pivotal role in the pathogenesis of this disease. In this study, we have identified secretion of interleukin-23 (IL-23) by donor antigen-presenting cells (APCs) as a critical event in the induction of GVHD of the colon linking conditioning regimen-induced mucosal injury and lipopoly-saccharide (LPS) translocation to subsequent proinflammatory cytokine production and GVHD-associated pathologic damage. In the absence of donor APC-derived IL-23 secretion, there is a selective and profound reduction in pathologic damage as well as a marked reduction in LPS and proinflammatory cytokine production in the colon microenvironment. The downstream proinflammatory effects of IL-23 are dependent upon donor-derived secretion of interferon-γ (IFN-γ), but are independent of donor IL-17 production. These findings define a novel organ-specific role for IL-23 in the pathophysiology of GVHD and demonstrate that IL-23 can direct tissue-specific pathology within the context of a systemic inflammatory disorder. Furthermore, these studies also identify IL-23 as a potential therapeutic target for the prevention of this life-threatening disorder.Keywords
This publication has 52 references indexed in Scilit:
- Interleukin-23 Restrains Regulatory T Cell Activity to Drive T Cell-Dependent ColitisImmunity, 2008
- Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host diseaseBlood, 2007
- The role of antigen-presenting cells in triggering graft-versus-host disease and graft-versus-leukemiaBlood, 2007
- Interleukin-23 drives innate and T cell–mediated intestinal inflammationThe Journal of Experimental Medicine, 2006
- Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitisJournal of Clinical Investigation, 2006
- IL-23 is essential for T cell–mediated colitis and promotes inflammation via IL-17 and IL-6Journal of Clinical Investigation, 2006
- Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cellsNature, 2006
- Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brainNature, 2003
- A new mathematical model for relative quantification in real-time RT-PCRNucleic Acids Research, 2001
- Prevention of Graft Versus Host Disease by Inactivation of Host Antigen-Presenting CellsScience, 1999